Moreover, additional technological advances in staging modalities such as prostate-specific membrane antigen positron emission computer tomography (PSMA-PET/CT) have shown superiority regarding accuracy, and sensitivity in initially diagnosed prostate cancer patients when compared to conventional staging modalities such as CT or bone scans [19]. The gene discussed is FOLH1; the disease is prostate carcinoma.